<DOC>
	<DOC>NCT02186145</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of association of metronidazole, nystatin and dexamethasone in the treatment of bacterial and fungal vaginal infections.</brief_summary>
	<brief_title>Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Postmenarche women and premenopausal women, between 18 and 50 years old; Diagnosis of bacterial vaginosis (Amsel criteria), fungal (positive KOH test)or mixed vaginal infection; Patients who have regular menstrual cycles (patients with regular menstrual cycles with intervals between 21 to 35 days, duration of 1 to 7 days) Patients who have a known hypersensitivity to components of the formula ; Pregnant and lactating women ; Patients with other vaginal infections, such as infection by Trichomonas vaginalis , C. trachomatis, Neisseria gonorrhoeae , herpes or HPV. Knowledge of positive test result for human immunodeficiency virus ; Patients in treatment of cervical intraepithelial neoplasia or carcinoma of the cervix ; Patients who have undergone gynecological procedures in the month prior to inclusion (such as cauterization of the cervix , cervical biopsy, highfrequency surgery) ; Patients with other vaginal or vulvar conditions that may confound interpretation of clinical response; Patients who received intravaginal or systemic antimicrobial or antifungal therapy 14 days before randomization ; Patients on immunosuppressive medications (such as corticosteroids , cyclosporine , etc. ) ; Known or suspected cancer ; Participation in any experimental study or ingestion of any experimental drug 12 months before the start of this study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>